| NDA No. | Drug | Applicant |
|---|---|---|
| 50–192 ..... | Tegopen Powder for Oral Solution ..... | Do. |
| 50–194 ..... | Prostaphlin Powder for Oral Solution ..... | Do. |
| 50–195 ..... | Prostaphlin (Oxacillin Sodium) for Injection ..... | Apothecon. |
| 50–308 ..... | Polycillin (Ampicillin) Powder for Oral Solution ..... | Do. |
| 50–337 ..... | Dynapen for Oral Suspension ..... | Do. |

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director of the Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 29, 1995.

Dated: September 21, 1995.

Janet Woodcock,

*Director, Center for Drug Evaluation and Research.*

[FR Doc. 95–24156 Filed 9–28–95; 8:45 am]

**BILLING CODE 4160–01–P**

**[Docket No. 95N–0318]**

## Searle, et al.; Withdrawal of Approval of 17 New Drug Applications

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 17 new drug applications (NDA's). The holders of the NDA's notified the agency in writing that the drug products were no longer being marketed under the NDA and requested that the approval of the applications be withdrawn.

**EFFECTIVE DATE:** September 29, 1995.

**FOR FURTHER INFORMATION CONTACT:** Nancy G. Maizel, Center for Drug Evaluation and Research (HFD–53), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2623.

**SUPPLEMENTARY INFORMATION:** The holders of the NDA's listed below have informed FDA that these drug products are no longer being marketed under the NDA and have requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing.

| NDA No. | Drug | Applicant |
|---|---|---|
| 2–386 ..... | Aminophyllin Tablets ..... | Searle, 4901 Searle Pkwy., Skokie, IL 60077 |
| 3–205 ..... | Pantholin Tablets ..... | Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285. |
| 6–917 ..... | Gantrisin Injection ..... | Hoffmann-La Roche Inc., Roche Pharmaceuticals, 340 Kingsland St., Nutley, NJ 07110–1199. |
| 8–867 ..... | Rauwiloid Tablets ..... | 3M Pharmaceuticals, 3M Center, St. Paul, MN 55144–1000. |
| 9–078 ..... | Parsidol Tablets ..... | Parke-Davis Pharmaceutical Research, 2800 Plymouth Rd., Ann Arbor, MI 48105. |
| 9–299 ..... | Hyperloid Tablets ..... | Person & Covey Inc., P.O. Box 25018, 616 Allen Ave., Glendale, CA 91221–5018. |
| 11–045 ..... | Milprem Tablets ..... | Wallace Laboratories, Division of Carter-Wallace Inc., 301B College Rd. East, Princeton, NJ 08540. |
| 11–110 ..... | Actidil Tablets ..... | Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700. |
| 11–496 ..... | Actidil Syrup ..... | Do. |
| 11–535 ..... | Equanil Meprobamate Suspension ..... | Wyeth-Ayerst Laboratories, P.O. Box 8299, Philadelphia, PA 19101–8299. |
| 11–876 ..... | Fedrazil Tablets ..... | Burroughs Wellcome Co. |
| 17–528 ..... | Uticort Lotion ..... | Parke-Davis Pharmaceutical Research. |
| 17–917 ..... | Duraquin Tablets ..... | Warner Chilcott Laboratories, 201 Tabor Rd., Morris Plains, NJ 07950. |
| 18–375 ..... | Turgex Bacteriostatic Skin Cleanser (Aerosol) ..... | Xttrium Laboratories Inc., 415 West Pershing Rd., Chicago, IL 60609. |
| 19–055 ..... | Turgex Bacteriostatic Skin Cleanser (Emulsion) ..... | Do. |
| 50–019 ..... | Penbritin Ampicillin Drops ..... | Wyeth-Ayerst Laboratories. |
| 50–355 ..... | Coly-Mycin S Oral Suspension ..... | Parke-Davis Pharmaceutical Research. |

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 29, 1995.

Dated: September 2, 1995.

Janet Woodcock,

*Director, Center for Drug Evaluation and Research.*

[FR Doc. 95–24157 Filed 9–28–95; 8:45 am]

**BILLING CODE 4160–01–P**

## Advisory Committees; Notice of Meetings

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone